Actinium reports complete response in the Actimab-A venetoclax combination trial

Actinium Pharmaceuticals has reported 67% overall response rate in first cohort in Actimab-A Venetoclax combination trial in relapsed and refractory AML at ASH, which includes one complete response in patient with TP53 mutation and one partial response reported in patients with poor risk adverse cytogenetics with subtherapeutic dose of Actimab-A indicative of mechanistic synergy with venetoclax.

Read more

Janssen Submits Application to U.S. FDA Seeking Approval of Amivantamab for the Treatment of Patients with Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of amivantamab for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy.

Read more

Understanding the role of inflammation in COVID-19 patients: a little is good, too much might kill you

COVID-19 is the medical emergency of the century. Since the pandemic began in December 2019, the new coronavirus, termed SARS-CoV-2 has caused havoc in almost every country, with more than 40 million proven cases of the disease termed COVID-19, including one million deaths.

Read more